{
    "nctId": "NCT05253066",
    "briefTitle": "Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer",
    "officialTitle": "An Open, Multicenter, Randomized Controlled Clinical Study of Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2, PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 130,
    "primaryOutcomeMeasure": "ORR",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* female patients aged greater than or equal to 18 years and less than or equal to 75 years, meet one of the following:\n\n  1. previous oophorectomy, or age \u2265 60 years;\n  2. age \\< 60 years, natural postmenopausal status (defined as at least 12 consecutive months of spontaneous cessation of regular menstruation, and no other pathological or physiological causes), E2 and FSH in postmenopausal levels;\n  3. premenopausal or perimenopausal female patients, must be willing to receive LHRH agonist therapy during the study;\n* all patients were confirmed by histopathology as estrogen receptor (ER) positive (\\> 10%), HER2 receptor negative.Follow the 2018 version of ASCO-CAP HER2-negative interpretation guideline criteria;\n* tumor stage II-III meeting the AJCC 8th version criteria, patients who have previously received 2 cycles of TE regimen chemotherapy, with disease evaluation of SD or PD;\n* KPS score \u2265 70 points;\n* organ function level must meet the following requirements:\n\n  1. bone marrow function ANC \u2265 1.5 \u00d7 109/L (14 without growth factors); PLT \u2265 100 \u00d7 109/L (7 without corrective treatment); Hb \u2265 100 g/L (7) without corrective treatment;\n  2. liver and kidney function TBIL \u2264 1.5 \u00d7 ULN; ALT and AST \u2264 3 \u00d7 ULN; BUN and Cr \u2264 1.5 \u00d7 ULN and creatinine clearance \u2265 50 mL/min (Cockcroft-Gault formula);\n* able to undergo needle biopsy;\n* voluntarily join this study, sign informed consent, have good compliance and are willing to cooperate with follow-up\n\nExclusion Criteria:\n\n* received any form of anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.);\n* received any other anti-tumor therapy at the same time;\n* breast cancer, inflammatory breast cancer or occult breast cancer;\n* stage IV breast cancer;\n* breast cancer without histopathological diagnosis;",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}